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Neomangiferin, a natural C-glucosyl xanthone, has recently received a great deal of attention due to its
multiple biological activities. In this study, a rapid and sensitive ultra-high performance liquid chroma-
tography tandem mass spectrometry (UHPLC–MS/MS) method for the quantiﬁcation of neomangiferin in
rat plasma was developed. Using chloramphenicol as an internal standard (IS), plasma samples were
subjected to a direct protein precipitation process using methanol (containing 0.05% formic acid). Quan-
tiﬁcation was performed by multiple reactions monitoring (MRM) method, with the transitions of the
parent ions to the product ions of m/z 583.1-330.9 for NG and m/z 321.1-151.9 for IS. The assay was
shown to be linear over the range of 0.2–400 ng/mL, with a lower limit of quantiﬁcation of 0.2 ng/mL. Mean
recovery of neomangiferin in plasma was in the range of 97.76%–101.94%. Relative standard deviations
(RSDs) of intra-day and inter-day precision were both o10%. The accuracy of the method ranged from
94.20% to 108.72%. This method was successfully applied to pharmacokinetic study of neomangiferin after
intravenous (2 mg/kg) and intragastric (10 mg/kg) administration for the ﬁrst time. The oral absolute
bioavailability of neomangiferin was estimated to be 0.53%70.08% with an elimination half-life (t1/2) value
of 2.7470.92 h, indicating its poor absorption and/or strong metabolism in vivo.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neomangiferin (NG) was ﬁrst extracted from the dried rhizome of
Anemarrhena asphodeloides, and its structure was conﬁrmed as a new
C-glucosyl xanthone in comprehensive spectral analysis [1]. There
have been previous studies reporting the extraction of NG from the
rhizome of Belamcanda chinensis [2] and Gentiana rhodantha [3]. Also,
the plant extracts which contain NG have already been widely used
for the treatment of diabetes [4,5] and osteoporosis [6]. However, the
pharmacological effects of NG have not been clearly deﬁned yet.
Zhou et al. [7] have demonstrated that NG has signiﬁcant therapeutic
effects on high-fat diet-induced nonalcoholic fatty liver disease
(NAFLD) in rats, suggesting that NG could play an important role in
modulating the mRNA and protein expression involved in free fatty
acid uptake, lipogenesis and lipid oxidation.
Despite the potential medical beneﬁts of NG, the possible me-
chanism is still complex and not fully understood yet. The con-
centration of NG in vivo is critical to its bioavailability, and theon and hosting by Elsevier B.V. Th
University.
).
.pharmacokinetic proﬁle is essential for a better understanding of
pharmacological and clinical effects of this active compound.
To the best of our knowledge, the information about the
pharmacokinetic properties of NG in raw materials and related
traditional Chinese prescriptions is already available [8,9].
There were several liquid chromatography coupled with tandem
mass spectrometry (LC–MS/MS) methods reported to quantify NG in
plasma. For example, Sun et al. [8] developed an LC–MS/MS method
for the quantiﬁcation of NG in rat plasma after oral administration of
A. asphodeloides extract and Er-Mu preparationwith totally more than
20min of running time. Li et al. [9] reported a method to detect NG in
rat plasma after oral administration of Baihe Zhimu Tang by LC–MS/
MS. But the method had some limitations, including long running
time (10 min), large volume of plasma sample (200 μL), inadequate
sensitivity (lower limit of quantiﬁcation (LLOQ): 10.3 ng/mL) and
narrow linear concentration range (10.3–1660 ng/mL). Obviously, the
pharmacokinetic properties of the constituent contained in crude
plant materials are quite different from those of respective pure
compounds, owing to the presence of multiple components [10].
However, until now, the pharmacokinetic characteristics of the pure
NG have not been investigated yet. Moreover, little information is
given on the quantiﬁcation and pharmacokinetic research of NG after
intravenous administration, which could not provide more essentialis is an open access article under the CC BY-NC-ND license
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Therefore, in this paper we were dedicated to developing and
validating a rapid, simple and sensitive ultra-high performance
liquid chromatography coupled with tandem mass spectrometry
(UHPLC–MS/MS) method for the determination of NG in rat plas-
ma after intravenous (2 mg/kg) and intragastric (10 mg/kg) ad-
ministration. The method has the advantages of small volume of
plasma sample (50 μL), simple sample preparation (one-step
protein precipitation), good chromatographic resolution, speciﬁc
and sensitive mass spectrometric conditions and short runtime
(4 min), with the concentration range of 0.2–400 ng/mL.2. Materials and methods
2.1. Chemicals and reagents
Reference standards of NG and chloramphenicol (internal
standard, IS) were purchased from Dingrui Pharmaceutical Co., Ltd
(Shanghai, China). Their purities were determined to be over 98%
by normalization of the peak areas detected by UHPLC–MS/MS.
Methanol, acetonitrile, ammonium acetate and formic acid of MS-
grade were purchased from Fisher Scientiﬁc (Tustin, CA, USA).
Ultra-pure water was prepared by Milli-Q System (Millipore,
Bedford, MA, USA). Other reagents used here were of analytical
grade.
2.2. Instrumentation and conditions
Chromatographic separations were performed on a Shimadzu
LC system (Kyoto, Japan) equipped with system controller (CBM-
20A), pump (LC-20ADXR), auto-injector (SIL-20AC), online de-
gasser (DGU-20A3), and column heater (CTO-20AC). Then se-
parations were achieved on a Poroshell 120 EC-C18 column
(100 mm3.0 mm, 2.7 mm; Agilent, USA) with an EC-C18 guard
column (5 mm2.1 mm, 2.7 mm; Agilent, USA). Isocratic analysis
was made through a mobile phase of solvent A (water containing
5 mM ammonium acetate)-solvent B (methanol containing 0.1%
formic acid) (10:90, v/v). The ﬂow rate was 0.6 mL/min and the
injection volume was 5 mL. The column and sample temperature
were maintained at 25 °C and 4 °C, respectively.
An AB SCIEX QTRAPs 5500 tandem mass spectrometer (AB,
USA) was connected to the LC system through an electrospray
ionization (ESI) interface. The ESI source was operated in negative
ionization mode. Quantiﬁcation was performed by multiple reac-
tions monitoring (MRM) method, with the transitions of the par-
ent ions to the product ions of m/z 583.1-330.9 for NG and m/z
321.1-151.9 for IS. The conditions of ionization source were as
follows: curtain gas, 25 psi; ion spray voltage, 4000 V; tempera-
ture, 500 °C, nebulizer gas, 35 psi; and heater gas, 60 psi.
Compound dependent parameters for NG included declustering
potential (DP): 134.2 V, entrance potential (EP): 10.4 V,
collision energy (CE): 51.6 V and collision exit potential (CXP):
36.3 V; for IS DP: 117.2 V, EP: 11.3 V, CE: 21.2 V and CXP:
15.4 V. System control and data analysis were performed by AB
Sciex Analyst software (version 1.6.1).
2.3. Standard solutions, calibration standards and quality control
Stock solutions of NG and IS were prepared in methanol at a
concentration of 1 mg/mL. Then the stock solutions were diluted
with methanol to obtain fresh standard working solutions. The
plasma calibration standard solutions were prepared at con-
centrations of 0.2, 0.4, 1, 4, 10, 40, 100 and 400 ng/mL for NG and
40 ng/mL for IS by spiking the moderate amounts of working so-
lutions into 50 mL of blank plasma.Low-, mid- and high-level quality control (QC) samples con-
taining 0.5, 10 and 320 ng/mL of NG were prepared in a manner
similar to that used for the preparation of calibration samples. All
stock solutions, working solutions, calibration standards and QC
samples were stored at 20 °C and were brought to room tem-
perature before analysis.
2.4. Sample preparation
Before analysis, the plasma sample was thawed to room tem-
perature. An aliquot of 50 mL of plasma was mixed with 50 mL of IS
working solution (40 ng/mL) and 400 mL of methanol (containing
0.05% formic acid). After vortexing for 2 min, the mixture was
centrifuged at 4 °C for 10 min at 13,000 g. The supernatant (5 mL)
was injected into the UHPLC–MS/MS system for analysis.
2.5. Method validation
The method was validated for selectivity, linearity, precision,
accuracy, matrix effect, recovery and stability according to the
guidelines set by the United States Food and Drug Administration
(USFDA) [11] and European Medicines Agency (EMA) [12] for the
validation of bioanalytical method. Validation runs were con-
ducted on three consecutive days. Each validation run consisted of
one set of calibration standards and six replicates of QC plasma
samples.
The selectivity of the method was evaluated by analyzing six
blank plasma samples from different rats, blank plasma spiked NG
and IS, as well as a rat plasma sample. The “cross-talk” between
MRM transitions was evaluated by analyzing these different blank
samples.
Calibration curves were constructed by analyzing spiked cali-
bration samples on three separate days. Peak area ratios of NG to
IS were plotted against analyte concentrations, and standard
curves were well ﬁtted to the equations by linear regression with a
weighting factor of the reciprocal of the concentration (1/x) in the
concentration range of 0.2–400 ng/mL. The limit of detection
(LOD) was determined as the plasma concentration giving a sig-
nal-to-noise ratio of 3 and the LLOQ was deﬁned as the lowest
concentration on the calibration curves; NG peak should be
identiﬁable, discrete, and reproducible with a precision of 20% and
accuracy of 80%–120%.
To evaluate the matrix effect, six blank plasma samples from
different rats were extracted and then spiked with the analyte at
0.5, 10 and 320 ng/mL. The corresponding peak areas were then
compared to those of neat standard solutions at equivalent con-
centrations, and this peak area ratio is deﬁned as the matrix effect.
The matrix effect of IS was evaluated at the concentration of
40 ng/mL in the same manner.
Accuracy and precision were assessed by the determination of
QC samples at three concentration levels (0.5, 10 and 320 ng/mL)
in six replicates on three validation days. The precision was ex-
pressed by relative standard deviation (RSD).
The recovery of NG was evaluated by comparing peak areas of
extracted QC samples with those of reference QC solutions re-
constituted in blank plasma extracts (n¼6). The recovery of IS was
determined in a similar way.
Carry-over was assessed following injection of two processed
blank matrix samples immediately after three repeats of the upper
limit of quantiﬁcation (ULOQ) and the response was checked [13].
Stability of NG in rat plasma was evaluated by analyzing three
replicates of plasma samples at the concentrations of 0.5, 10 and
320 ng/mL, which were exposed to different conditions. These
results were compared with those of freshly prepared plasma
samples. The short-term stability was determined after the ex-
posure of the spiked samples to room temperature for 4 h, and the
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tosampler at room temperature for 24 h. The freeze/thaw stability
was evaluated after three complete freeze/thaw cycles (20 to
25 °C) on consecutive days. The long-term stability was assessed
after storage of the standard spiked plasma samples at 20 °C for
30 days.
If the concentration in a real sample was above the ULOQ, the
sample was analyzed after dilution with blank plasma. The dilu-
tion integrity experiment was carried out at 5 times of the ULOQ
concentration (2000 ng/mL) and also at ULOQ level (400 ng/mL).
Six replicate samples, each of which has the concentration of 1/10
of 5ULOQ (200 ng/mL) and ULOQ concentration (40 ng/mL),
were prepared and their concentrations were calculated, by ap-
plying the dilution factor against the freshly prepared calibration
curve for NG. The percentage change from the comparison sample
should be within 715%.
2.6. Pharmacokinetic study
Male Sprague-Dawley (SD) rats (body weight: 200720 g) were
obtained from Third Military Medical University (Chongqing,
China). All animals were bred in a breeding room at 2572 °C with
60%75% humidity, and a 12 h dark-light cycle. The animals were
acclimatized to the facilities for 5 days, and then fasted with free
access to water for 12 h prior to each experiment. The dosing so-
lution of NG was prepared by dissolving appropriate amount of NG
in 0.5% carboxymethyl cellulose sodium (CMC-Na) aqueous solu-
tion. All rats were randomized into two groups (six in each group):
NG 2 mg/kg body weight by intravenous administration and
10 mg/kg body weight by intragastric administration, respectively.
The intravenous solution injection rate was controlled within
1 min. After a single dose was administered, about 300 mL of blood
samples were collected in heparinized tubes via the orbital vein at
0 (predose), 0.033, 0.083, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10
and 12 h for intravenous administration and 0 (predose), 0.083,
0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10 and 16 h for intragastric
administration, respectively. Following centrifugation at 2200 g at
4 °C for 3 min, plasma samples were obtained and frozen at
20 °C until analysis.
Pharmacokinetic parameters were determined by non com-
partmental methods using the Drug and Statistics software (DAS,
version 2.0, Clinical Drug Evaluation Center, Wannan Medical
College, Anhui, China). The pharmacokinetic parameters, such as
maximum plasma concentration (Cmax) and time of maximum
concentration (Tmax), were obtained directly from the plasma
concentration-time plots. The elimination rate constants (k) were
determined by linear regression analysis of the logarithmic
transformation of the last four data points of the curve. TheFig. 1. Full-scan product ion spectra of [M–H] ions and fragmelimination half-life (t1/2) was calculated using the following
equation: t1/2¼0.693/K. The area under the plasma concentration-
time curve up to the last time (t) (AUC0–t) was determined using
the trapezoidal rule. The AUC0-∞ values were calculated by adding
the value of Ct k1 to AUC0–∞. Bioavailability (F) was calculated
by (AUCig/AUCiv) (doseiv/doseig)100%.3. Results and discussion
3.1. Method development and optimization
The ion intensities of both NG and IS were high in the negative
ionization mode. [M–H] was selected as the precursor ion, and
the most speciﬁc fragment ions were selected as the product ions
in MRM acquisition to avoid any interference from the matrix. As a
result, the MRM transitions on the negative ionization of NG and IS
were selected at m/z 583.1/330.9 and m/z 321.1/151.9, respectively
(Fig. 1).
The mobile phase played a critical role in achieving good
chromatographic behavior and appropriate ionization [14]. Var-
ious combinations of organic diluents (methanol/acetonitrile) to-
gether with ammonium acetate or formic acid were investigated.
Methanol (containing 0.1% formic acid) and water (containing
5 mM ammonium acetate) were chosen as the mobile phase be-
cause they could provide symmetrical and sharp peak shape. As
isocratic elution is simple and provides relatively short running
time without column equilibration/re-equilibration time, isocratic
elution was used in the present assay and it did not encounter any
issues associated with possible buildup of contaminants or en-
dogenous components during each run. Because one analytical run
could be ﬁnished within 4 min, our method enabled a sample
throughput of at least 250 samples per day.
3.2. Method validation
3.2.1. Selectivity and matrix effect
Fig. 2 shows the typical chromatograms of a blank plasma
sample, a blank plasma sample spiked with NG and IS, and a
plasma sample. No interfering endogenous substance was ob-
served at the retention time of the analyte and IS.
To investigate the matrix effect, three concentration levels of
NG (0.5, 10 and 320 ng/mL) in six replicates were analyzed, and
the values are shown in Table 1. The matrix effects for NG and IS
ranged from 89.44% to 113.03%, and the corresponding RSDs were
less than 6.35%. Besides, the matrix effects for the dosing for-
mulation CMC-Na and the anticoagulant heparin sodium that
might exist in plasma were investigated as well, and no signiﬁcantentation schemes for (A) NG and (B) chloramphenicol (IS).
Fig. 2. Representative MRM chromatograms of (A) a blank rat plasma sample; (B) a blank rat plasma spiked with NG at LLOQ (0.2 ng/mL) and IS (40 ng/mL); (C) a rat plasma
sample at 0.5 h after an intravenous dose of NG (2 mg/kg) to rats and (D) a rat plasma sample at 0.5 h after an intravenous dose of NG (10 mg/kg) to rats (I: retention time,
1.54 min; m/z 583.1-330.9 for NG and II: retention time, 1.78 min; m/z 321.1-151.9 for IS).
Table 1
Matrix effect of NG and IS.
Compound Nominal con-
centration
(ng/mL)
Observed con-
centration
(ng/mL)
RSD (%) Matrix effect (%)
Neomangiferin 0.5 0.4570.01 2.77 89.4472.48
10 10.9370.18 1.67 109.3071.82
320 307.6879.37 3.05 96.1572.93
IS 40 45.2172.87 6.35 113.0377.18
B. Yang et al. / Journal of Pharmaceutical Analysis 6 (2016) 335–340338interference of these reagents was found. These results demon-
strated that the processing procedure of plasma samples was
highly acceptable with no signiﬁcant ion suppression or
enhancement.
3.2.2. Linearity and sensitivity
The linear regressions of the peak area ratios versus con-
centrations were ﬁtted over the concentration range 0.2–
400 ng/mL for NG in rat plasma. A typical equation of the cali-
bration curve was obtained as follows: y¼0.0393xþ0.00911
(r¼0.9993), where y is the peak-area ratio of NG to IS and x is the
plasma concentration of NG, respectively.
The LLOQ for NG was 0.2 ng/mL, which was sensitive enough
for the pharmacokinetic study of NG in rats. The precision and
accuracy at this concentration level were acceptable, with the RSD
of 11.5% and the accuracy of 98.2%, respectively. The LOD, deﬁned
as a signal/noise ratio of 3, was 0.1 ng/mL for NG in rat plasma.
3.2.3. Precision and accuracy
The intra- and inter-day precision and accuracy of the methodTable 2
Accuracy and precision for the analysis of NG in QC samples.
Spiked concentra-
tion (ng/mL)
Found concentra-
tion (ng/mL)
Accuracy (%) Precision (%RSD)
Intra-day
(n¼6)
Inter-day
(n¼3)
0.5 0.4770.04 94.20 8.13 3.10
10 10.8770.21 108.72 1.93 4.20
320 345.9278.59 108.10 2.48 4.79were investigated by analyzing QC samples (0.5, 10 and
320 ng/mL). All the values are shown in Table 2. Intra-day RSD was
below 8.13% and inter-day RSD was below 4.79%. The accuracy was
within 94.20%–108.72%. The method was proved to be highly ac-
curate and precise.
3.2.4. Extraction recovery and stability
The extraction recoveries of NG were 97.76%72.81%, 101.67%
72.15% and 101.94%73.84% at three concentrations of 0.5, 10 and
320 ng/mL, respectively, while the recovery of IS was 103.49%
76.49%. These results suggested that the recoveries of NG and IS
were consistent and were not concentration-dependent. All the
values are shown in Table 3.
The autosampler, room temperature, freeze-thaw and long-
term (30 days) stability results indicated that the analyte was
stable under the storage conditions described above since the bias
in concentration was within 715% of nominal values (Table 4).
3.2.5. Carry-over
Carry-over was tested by injecting two processed blank matrix
samples subsequently after injection of a ULOQ sample in three
independent runs. The response in the ﬁrst blank matrix at the
retention time of NG should be less than 20% of the mean response
of an LLOQ sample for NG. The response in the ﬁrst blank matrix at
the retention time of the analyte was less than 4.7% of the mean
response at the LLOQ for NG. Therefore, the carry-over test was
found to be acceptable.
3.2.6. Cross-talk
The phenomenon of cross-talk may have occurred if the ana-
lytes had similar retention time, which will lead to greater de-
viation of the results. Therefore, it is essential to monitor two orTable 3
Recoveries of NG and IS (n¼6).
Compounds Concentration (ng/mL) RSD (%) Recovery (%, mean7SD)
Neomangiferin 0.5 2.87 97.7672.81
10 2.11 101.6772.15
320 3.77 101.9473.84
IS 40 6.27 103.4976.49
Table 4
Stability of quality control samples of NG (n¼6).
Condition Concentration (ng/mL) CV (%) Accuracy (%)
Nominal Found
Short-term stability (4 h at
room temperature)
0.5 0.4870.01 1.71 95.52
10 10.7470.37 3.43 107.36
320 347.8475.21 1.50 108.70
Autosampler stability (24 h
at room temperature)
0.5 0.4770.02 4.85 93.00
10 10.6270.23 2.15 106.16
320 341.3674.67 1.37 106.68
Freeze-thaw stability (three
cycles)
0.5 0.4670.02 3.77 91.96
10 10.8870.20 1.79 108.79
320 352.3577.60 2.16 110.10
Long-term stability (30 days
at 20 °C)
0.5 0.4770.02 5.07 93.80
10 10.3470.13 1.25 103.44
320 318.4877.26 2.28 99.53
Table 5
Pharmacokinetic parameters of NG after intravenous (2 mg/kg) and intragastric
(10 mg/kg) administrations in rats (mean7SD, n¼6).
Parameters Intravenous Intragastric
t1/2 (h) 1.7070.14 2.7470.92
C2min (ng/mL) 6330.117854.68 –
Tmax (h) – 0.5870.29
Cmax (ng/mL) – 72.1777.97
AUC0–t (ng h/mL) 3484.317324.58 92.26717.53
AUC0–∞ (ng h/mL) 3487.247325.28 93.31717.53
Vz (L/kg) 1.4170.06 –
MRT (h) 2.5470.41 3.7670.92
F (%) 0.5370.08
t1/2: elimination half-time; C2min: the observed plasma concentration at 2 min;
Tmax: time to peak value; Cmax: peak concentration; AUC0–t: area under the plasma
concentration-time curve from time zero to t; AUC0–∞: area under the curve from
time zero to inﬁnity; Vz:apparent volume of distribution.; MRT: mean residence
time; F: bioavailability.
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methods are usually used to avoid cross-talk: selecting different
quantitated ions to improve the selectivity; and optimizing the
mobile phase to completely separate the analytes [15]. In the
present study, NG and IS had different quantitated ions and re-
tention time (tR¼1.54 min for NG, and tR¼1.78 min for IS). The
results indicated that there was no interference between the four
monitoring channels, and no relevant cross-talk was observed.
3.2.7. Dilution integrity
The mean back-calculated concentrations for 1/10 dilution
samples of 5ULOQ and ULOQ were 96.1% and 97.2%, respectively.
The RSDs were 9.5% and 7.4%, respectively.
3.3. Application of the method to pharmacokinetic study
The method was successfully applied to the quantiﬁcation of
NG in rat plasma after intravenous (2 mg/kg) and intragastric
dosings (10 mg/kg). Intravenous dose was limited by NG solubility
in a vehicule compatible with this administration route. Antici-
pating a possibly low bioavailability, a higher dose was chosen for
oral administration in order to make quantitation possible. These
doses were based on the tolerance observed in previous experi-
ments (unpublished results). Indeed, no sign of acute toxicity was
observed at these doses. The mean plasma concentration-time
curves are shown in Fig. 3. An important inter-individual varia-
bility was observed for both intravenous and intragastric
administrations.
The main pharmacokinetic parameters from non-compartment
model analysis are summarized in Table 5. The absoluteFig. 3. Mean plasma concentration-time curves of NG in rats following (A) intravenobioavailability of NG was calculated to be 0.53%70.08%. Many
factors that could be responsible for the low bioavailability of this
compound include the potential hydrolysis in the gastrointestinal
tract, poor permeability through the intestinal epithelial mem-
brane and ﬁrst-pass effect in the liver [16]. Thus, the aglycone of
NG or its other metabolites that might exist in plasma may be paid
more attention to in our further studies. In addition, our results
further support efﬁcacy results following intravenous
administration.
There have been some references on determination of NG after
intragastric administration of A. asphodeloides extract and related
traditional Chinese prescriptions in rat plasma [8,9]. But no
method about determination of pure NG in plasma is available in
the literatures. The pharmacokinetic proﬁles of NG in raw mate-
rials or prescriptions were slightly different from that observed in
pure form, and the possible reasons might be the complexity of
Traditional Chinese Medicine (TCM) for their interaction between
multitudinous compounds in formulas in vivo.4. Conclusion
This developed method was shown to be speciﬁc, sensitive,
precise and accurate for the quantiﬁcation of NG in rat plasma.
This method represented an improvement over the previous
published procedures [8,9] in the following aspects: (i) sample
preparation by fast and cheap protein precipitation with methanol
(containing 0.05% formic acid) had no inﬂuence on the recovery of
the analyte and therefore caused no detectable matrix effects;us (2 mg/kg) and (B) intragastric (10 mg/kg) administrations (mean7SD, n¼6).
B. Yang et al. / Journal of Pharmaceutical Analysis 6 (2016) 335–340340(ii) this method featured the highest sensitivity with an LLOQ of
0.2 ng/mL so far; (iii) run time of only 4 min enabled a high sample
throughput of at least 250 samples per day; and (iv) in contrast to
all other published methods, our method was comprehensively
validated according to the current USFDA and EMA guidelines for
bioanalytical method validation. The established method has al-
ready been successfully applied to a pharmacokinetic study of NG
after intravenous (2 mg/kg) and intragastric (10 mg/kg) adminis-
trations to rats. The pharmacokinetic proﬁle of NG in rat was
characterized and the bioavailability of NG was reported to be
0.53%70.08% for the ﬁrst time. Due to the poor bioavailability of
NG, more attention should be paid to the metabolites of NG that
might exist in plasma in our further studies.Acknowledgments
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